000 | 01948 a2200565 4500 | ||
---|---|---|---|
005 | 20250514163717.0 | ||
264 | 0 | _c20040105 | |
008 | 200401s 0 0 fre d | ||
022 | _a0020-2509 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aChahed, M K | |
245 | 0 | 0 |
_a[Efficacy of intra-lesional glucantime in the treatment of zoonotic cutaneous leishmaniasis in basic health care conditions]. _h[electronic resource] |
260 |
_bArchives de l'Institut Pasteur de Tunis _c |
||
300 |
_a13-8 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
650 | 0 | 4 |
_aAntiprotozoal Agents _xadministration & dosage |
650 | 0 | 4 | _aDrug Resistance, Bacterial |
650 | 0 | 4 |
_aEosine Yellowish-(YS) _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInjections, Intralesional |
650 | 0 | 4 | _aLeishmania major |
650 | 0 | 4 |
_aLeishmaniasis, Cutaneous _xcomplications |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMeglumine _xadministration & dosage |
650 | 0 | 4 | _aMeglumine Antimoniate |
650 | 0 | 4 |
_aOrganometallic Compounds _xadministration & dosage |
650 | 0 | 4 | _aPrimary Health Care |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aSingle-Blind Method |
650 | 0 | 4 |
_aStaphylococcal Infections _xdrug therapy |
650 | 0 | 4 |
_aStreptococcal Infections _xdrug therapy |
650 | 0 | 4 | _aStreptococcus pyogenes |
650 | 0 | 4 |
_aSuperinfection _xdrug therapy |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 | _aTunisia |
650 | 0 | 4 |
_aZoonoses _xparasitology |
700 | 1 | _aBen Salah, A | |
700 | 1 | _aLouzir, H | |
700 | 1 | _aMarrakchi, H | |
700 | 1 | _aZaatour, A | |
700 | 1 | _aFtaïti, A | |
700 | 1 | _aBen Chaabane, B | |
700 | 1 | _aSidhom, M | |
700 | 1 | _aDellagi, K | |
700 | 1 | _aBen Ismail, R | |
773 | 0 |
_tArchives de l'Institut Pasteur de Tunis _gvol. 76 _gno. 1-4 _gp. 13-8 |
|
999 |
_c14399658 _d14399658 |